Department of Pediatrics, Shengjing Hospital of China Medical University, Shenyang, China.
Front Endocrinol (Lausanne). 2021 Sep 3;12:737527. doi: 10.3389/fendo.2021.737527. eCollection 2021.
To analyze the clinical characteristics of Hashimoto's thyroiditis (HT) in children below 3 years of age in order to improve the understanding of the disease, avoid misdiagnosis, and achieve early diagnosis and treatment.
The study retrospectively analyzed the clinical data of 19 patients diagnosed with HT in the first three years of life.
The patients (12 female, 7 male) had an average age of 26.1 ± 8.2 months (range 10-36 months). At presentation, one patient had euthyroidism, ten had hypothyroidism, seven had subclinical hypothyroidism, and one had hyperthyroidism. The most common reasons for doctor's visits were thyroid enlargement (21.1%), global developmental delay (21.1%), and routine thyroid function tests in patients with type 1 diabetes (26.3%). Sixteen patients provided follow-up data, and the mean follow-up time was 23.31 ± 16.44 months (range 1-48 months). In the hypothyroidism group, one patient stopped levothyroxine (LT4) treatment after 2 months; the remaining patients had been treated with LT4 since their diagnosis. In the subclinical hypothyroidism group, one patient whose thyroid function returned to normal after 1 month of being diagnosed was not treated. The remaining patients received LT4 treatment at their diagnosis or during follow-up. The patient with hyperthyroidism was treated with methimazole after diagnosis, but treatment was discontinued 11 months later and LT4 was initiated 26 months after diagnosis. One in four patients with global developmental delay approached normal mental development after LT4 treatment. Four in six patients with short stature achieved height catch-up.
At their initial HT diagnosis, most of the children showed hypothyroidism or subclinical hypothyroidism. Children with global developmental delay require continual screening, even if the thyroid function is normal after birth, to determine whether they have HT-induced hypothyroidism. Thyroxine replacement could partially relieve the clinical manifestations of hypothyroidism and early diagnosis and treatment are essential for improving patient prognosis.
分析 3 岁以下儿童桥本甲状腺炎(HT)的临床特征,提高对该病的认识,避免误诊,实现早期诊断和治疗。
本研究回顾性分析了 19 例初诊年龄在 3 岁以下的 HT 患儿的临床资料。
患儿(女 12 例,男 7 例)平均年龄为 26.1±8.2 个月(10~36 个月)。就诊时,1 例患儿为甲状腺功能正常,10 例患儿为甲状腺功能减退,7 例患儿为亚临床甲状腺功能减退,1 例患儿为甲状腺功能亢进。就诊的最常见原因分别为甲状腺肿大(21.1%)、全面发育迟缓(21.1%)和 1 型糖尿病患儿常规甲状腺功能检查(26.3%)。16 例患儿提供了随访资料,平均随访时间为 23.31±16.44 个月(1~48 个月)。在甲状腺功能减退组中,1 例患儿在 2 个月后停止了左甲状腺素(LT4)治疗;其余患儿在诊断后一直接受 LT4 治疗。在亚临床甲状腺功能减退组中,1 例患儿在诊断后 1 个月甲状腺功能恢复正常,未进行治疗。其余患儿在诊断时或随访期间接受了 LT4 治疗。诊断后,1 例甲状腺功能亢进患儿接受了甲巯咪唑治疗,但 11 个月后停药,26 个月后开始 LT4 治疗。接受 LT4 治疗后,四分之一的全面发育迟缓患儿的精神发育接近正常。六分之四的身材矮小患儿身高追赶成功。
初诊时,大多数患儿表现为甲状腺功能减退或亚临床甲状腺功能减退。全面发育迟缓的患儿需要持续筛查,即使出生后甲状腺功能正常,也要确定其是否存在 HT 引起的甲状腺功能减退。甲状腺素替代治疗可以部分缓解甲状腺功能减退的临床表现,早期诊断和治疗对改善患儿预后至关重要。